Sanofi’s oral BTK inhibitor rilzabrutinib fails Phase III trial
Rilzabrutinib missed primary and secondary endpoints as a treatment for pemphigus
Read More
Tag: rilzabrutinib
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
